Study guide

9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins

Key Takeaways Explain This Topic AI

Cyanide halts cellular aerobic respiration by binding ferric iron (Fe3+) in mitochondrial cytochrome c oxidase (complex IV), producing profound lactic acidosis and elevated central venous oxygen saturation (ScvO2 >90%) due to histotoxic cellular asphyxiation.

Hydroxocobalamin (Cyanokit, 5 g IV over 15 minutes, repeatable once) is the first-line antidote for cyanide poisoning in smoke inhalation victims, forming cyanocobalamin without inducing methemoglobinemia; notable adverse effects include chromaturia, skin erythema, and analytical interference with hemodialysis machines and colorimetric lab assays.

Sodium nitrite induces methemoglobinemia to bind cyanide but is strictly contraindicated in smoke inhalation victims due to concurrent carboxyhemoglobinemia; sodium thiosulfate serves as a sulfur donor for enzymatic rhodanese conversion to excreted thiocyanate.

Carbon monoxide binds hemoglobin with 200-250 times greater affinity than oxygen, shifting the oxyhemoglobin dissociation curve leftward; high-flow 100% normobaric oxygen reduces CO half-life to 60-90 minutes, whereas hyperbaric oxygen (HBO) reduces it to 20-30 minutes and is indicated for COHb >25% (>15% in pregnancy), syncope, neurologic deficits, or myocardial ischemia.

Organophosphates irreversibly inhibit acetylcholinesterase, producing life-threatening muscarinic 'Killer Bs' (bronchorrhea, bronchospasm, bradycardia) and nicotinic paralysis; management mandates escalating doses of atropine (2-5 mg IV q3-5min, doubled until pulmonary secretions are dry) combined with pralidoxime (2-PAM, 1-2 g IV then 500 mg/h infusion) administered prior to chemical aging.

Last updated: October 2026

9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins

Note

Independent BCEMP study resource provided by ExamFinch. Content covers emergency toxicology, specialized antidotes, and clinical pharmacotherapy principles.

Toxic inhalations and chemical agent exposures represent hyperacute emergencies where severe tissue hypoxia develops despite normal or elevated arterial partial pressure of oxygen. Cyanide and carbon monoxide are classic cellular asphyxiants commonly encountered in structure fires and industrial disasters, while organophosphates and carbamates precipitate catastrophic cholinergic crises through neuromuscular and parasympathetic exhaustion. Emergency medicine pharmacists must rapidly differentiate these toxidromes, initiate target-specific antidotes, and recognize laboratory interferences and treatment boundaries.

Cyanide Toxicity: Cellular Asphyxiation & Rapid Antidote Therapy

Cyanide is among the most rapidly lethal poisons known. Common clinical exposure routes include:

Smoke Inhalation from Structure Fires : Combustion of synthetic polymers containing carbon and nitrogen (polyurethane foams in furniture, plastics, wool, silk, vinyl, and nylon upholstery) produces high concentrations of hydrogen cyanide gas.

Industrial & Chemical Exposures : Metal plating, jewelry cleaning, chemical synthesis, metallurgy, and cyanide salts.

Pharmacologic Sources : Prolonged or high-dose continuous intravenous infusions of sodium nitroprusside ( > 2 mcg/kg/min >2\text{ mcg/kg/min} > 2 mcg/kg/min for > 48 hours >48\text{ hours} > 48 hours , or lower doses in patients with severe hepatic or renal dysfunction). Each molecule of sodium nitroprusside non-enzymatically releases five cyanide ions.

Ingestion of Cyanogenic Glycosides : Plants such as cassava root, apricot kernels, bitter almonds, and peach pits contain amygdalin, which gut flora hydrolyze into free cyanide.

Molecular Mechanism: The Cytochrome c Oxidase Blockade

Cyanide diffuses rapidly across cell membranes and binds with high affinity to the ferric iron ( Fe 3 + \text{Fe}^{3+} Fe 3 + ) moiety of cytochrome c c c oxidase (Complex IV) within the inner mitochondrial membrane. This binding arrests the terminal step of the mitochondrial electron transport chain, blocking the reduction of molecular oxygen to water: MITOCHONDRIAL ELECTRON TRANSPORT CHAIN BLOCKADE

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ Complex I ──> Complex II ──> Complex III ──> Complex IV (Cyt c Oxidase) ──x │
  • │ ▲ │
  • │ CYANIDE BINDS Fe3+ │
  • │ [Halts Aerobic Respiration & ATP Synthesis] │
  • └─────────────────────────────────────────────────────────────────────────────┘

Halting the electron transport chain completely shuts down oxidative phosphorylation. Cells immediately shift to anaerobic glycolysis to generate ATP, resulting in massive lactic acid production. Because peripheral tissues cannot extract or utilize oxygen from circulating oxyhemoglobin, oxygen remains trapped in the venous blood. This state is termed histotoxic hypoxia (cellular asphyxiation):

Diagnostic Hallmark : Severe high-anion-gap lactic acidosis (lactate often > 8 to 10 mmol/L >8\text{ to }10\text{ mmol/L} > 8 to 10 mmol/L in fire victims strongly correlates with blood cyanide levels > 40 mcmol/L >40\text{ mcmol/L} > 40 mcmol/L ). A plasma lactate level ≥ 10 mmol/L \ge 10\text{ mmol/L} ≥ 10 mmol/L in smoke inhalation victims without severe burns has a sensitivity > 85 % >85\% > 85% for toxic cyanide exposure.

Venous-Arterial Oxygen Gradient : Markedly narrowed; central venous oxygen saturation ( ScvO 2 \text{ScvO}_2 ScvO 2 ​ ) is characteristically elevated ( > 90 % >90\% > 90% ), and retinal and venous blood appears bright arterial red.

Antidote Resuscitation: Hydroxocobalamin (Cyanokit)

Hydroxocobalamin is the first-line antidote of choice for cyanide toxicity, especially in victims of closed-space structure fires who may have concurrent carbon monoxide poisoning.

Mechanism : Hydroxocobalamin contains a cobalt ion within a porphyrin ring that binds free cyanide with an affinity higher than that of cytochrome oxidase. The reaction forms cyanocobalamin (Vitamin B 12 \text{B}_{12} B 12 ​ ) , which is non-toxic and eliminated in the urine via renal filtration.

Dosing & Administration : Standard adult dose is 5 g IV (two 2.5 g vials, each reconstituted with 100 mL of 0.9% sodium chloride, lactated Ringer's, or D 5 W \text{D}_5\text{W} D 5 ​ W ) infused over 15 minutes . A second 5 g dose can be administered over 15 minutes to 2 hours for patients in cardiac arrest or with refractory hemodynamic instability (maximum cumulative dose 10 g ). Pediatric dosing is 70 mg/kg IV (maximum single dose 5 g).

Adverse Effects : Marked chromaturia (dark red, burgundy urine lasting up to 35 days), widespread reddish skin erythema and mucous membrane discoloration, transient hypertension (due to scavenging of endogenous nitric oxide), and pustular rash.

Warning

Hydroxocobalamin Analytical and Hemodialysis Machine Interference Because of its intense deep red color and spectrophotometric absorption properties, hydroxocobalamin interferes with colorimetric laboratory assays and medical devices for several days post-infusion:

Falsely elevates : Total bilirubin, serum creatinine, urine protein, and carboxyhemoglobin on co-oximetry.

Falsely lowers : Serum ALT and AST on specific platforms.

CRRT / Hemodialysis Interference : Blood leak detectors on continuous renal replacement therapy (CRRT) and intermittent hemodialysis machines use optical sensors that mistake the deep red blood/effluent for an acute dialyzer membrane rupture, triggering false blood-leak alarms and automated machine shutdowns . Dialysis teams must disable optical leak sensors or switch to alternative membrane modalities.

Alternative & Adjunctive Antidotes: The Nitrite-Thiosulfate Regimen

Before hydroxocobalamin became standard, the traditional Cyanide Antidote Kit comprised amyl nitrite, sodium nitrite, and sodium thiosulfate:

Sodium Nitrite (300 mg IV over 5–10 min; pediatrics 6–10 mg/kg) :

Mechanism : Oxidizes the ferrous iron ( Fe 2 + \text{Fe}^{2+} Fe 2 + ) in normal hemoglobin to ferric iron ( Fe 3 + \text{Fe}^{3+} Fe 3 + ) , generating methemoglobin (MetHb) . Methemoglobin has a higher affinity for cyanide than cytochrome oxidase, drawing cyanide out of mitochondria to form cyanomethemoglobin.

ABSOLUTE CONTRAINDICATION in Smoke Inhalation : In victims of fires, co-existing carbon monoxide poisoning creates carboxyhemoglobin (COHb), which impairs oxygen delivery. Inducing methemoglobinemia with sodium nitrite destroys the remaining functional oxygen-carrying capacity, precipitating fatal tissue anoxia. Sodium nitrite also causes severe vasodilation and hypotension.

Sodium Thiosulfate (12.5 g IV [50 mL of 25% solution] over 10–30 min) :

Mechanism : Acts as an exogenous sulfur donor for the endogenous mitochondrial enzyme rhodanese (thiosulfate sulfurtransferase). Rhodanese converts toxic cyanide into thiocyanate , which is 200-fold less toxic and safely excreted in the urine.

Clinical Role : Slower onset of action compared to hydroxocobalamin; however, it does not induce methemoglobinemia and can be co-administered safely with hydroxocobalamin or nitrites to enhance clearance.

Carbon Monoxide (CO) Poisoning

Carbon monoxide is an odorless, colorless, tasteless, non-irritating toxic gas produced by incomplete combustion of hydrocarbons. Common sources include faulty home furnaces, unvented space heaters, motor vehicle exhaust, generators in enclosed spaces, structure fires, and methylene chloride paint strippers (metabolized to CO by hepatic CYP2E1).

Pathophysiology & The Oxyhemoglobin Shift

Extreme Hemoglobin Affinity : CO binds to the iron atom in hemoglobin with 200 to 250 times greater affinity than molecular oxygen, forming carboxyhemoglobin (COHb) .

Leftward Shift of the Oxyhemoglobin Dissociation Curve : The binding of CO to one of the four heme sites alters hemoglobin's quaternary conformation, dramatically increasing the binding affinity of the remaining three heme sites for oxygen. This prevents oxygen release to hypoxic tissues, severely starving the brain and myocardium of oxygen.

Cellular & Mitochondrial Toxicity : Dissolved CO binds myoglobin (reducing cardiac contractility), inhibits mitochondrial cytochrome oxidase, and triggers leukocyte adhesion, xanthine oxidase activation, and lipid peroxidation, culminating in Delayed Neurological Sequelae (DNS) (cognitive deficits, personality changes, parkinsonism developing 2 to 40 days post-exposure). CARBON MONOXIDE ELIMINATION HALF-LIFE DYNAMICS

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ Ambient Room Air (21% FiO2): Half-Life ~300 minutes (4–5 hours)│
  • │ 100% Normobaric Oxygen (Non-Rebreather): Half-Life ~60 to 90 minutes │
  • │ Hyperbaric Oxygen (HBO, 2.5 to 3.0 ATA): Half-Life ~20 to 30 minutes │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Clinical Presentation & Diagnostic Evaluation

Symptoms : Mild toxicity presents with frontal headache, nausea, malaise, and dizziness (often misdiagnosed as viral influenza). Severe toxicity manifests as confusion, syncope, seizures, coma, acute myocardial ischemia, and cardiac arrest. "Cherry-red" skin is an exceedingly rare, late, post-mortem finding and must never be relied upon.

Standard Pulse Oximetry ( SpO 2 \text{SpO}_2 SpO 2 ​ ) is Falsely Normal : Standard two-wavelength pulse oximeters cannot distinguish between oxyhemoglobin and carboxyhemoglobin (both absorb light at 660 nm). A patient dying of severe CO poisoning may demonstrate an SpO 2 \text{SpO}_2 SpO 2 ​ of 99 % 99\% 99% .

Diagnostic Standard : Arterial or venous blood gas with co-oximetry , which measures the actual absorption spectrum across multiple wavelengths to directly calculate percentage carboxyhemoglobin (COHb). Baseline COHb is < 2 % <2\% < 2% in non-smokers and up to 5 to 10 % 5\text{ to }10\% 5 to 10% in heavy tobacco smokers.

Oxygen Therapy & Hyperbaric Oxygen (HBO) Protocol

Oxygen is the competitive antagonist that displaces CO from hemoglobin:

First-Line : Administer 100% normobaric oxygen via a tight-fitting non-rebreather reservoir mask immediately upon suspicion until the patient is completely asymptomatic and COHb is < 5 % <5\% < 5% .

Indications for Emergent Hyperbaric Oxygen (HBO at 2.5 to 3.0 ATA)

Carboxyhemoglobin level > 25 % >25\% > 25% in non-pregnant patients.

Carboxyhemoglobin level > 15 % >15\% > 15% in pregnant patients (fetal hemoglobin binds CO with higher affinity and has slower clearance; fetal death can occur even with mild maternal symptoms).

History of loss of consciousness (syncope) , transient or prolonged.

Neurological deficits , coma, seizures, or persistent altered mental status despite 100% normobaric oxygen.

Evidence of acute myocardial ischemia (ischemic ECG changes, chest pain, or elevated cardiac troponin).

Severe persistent metabolic acidosis (arterial pH < 7.25 \text{pH} < 7.25 pH < 7.25 ).

Tip

Hyperbaric oxygen within 24 hours of exposure significantly reduces the incidence of Delayed Neurological Sequelae (DNS) compared to normobaric oxygen alone by displacing CO, reversing cytochrome inhibition, and suppressing cerebral lipid peroxidation.

Organophosphate & Carbamate Toxicity: Cholinergic Poisoning

Organophosphates (chlorpyrifos, malathion, parathion, diazinon, and chemical warfare nerve agents such as sarin, VX, soman, and tabun) and carbamates (carbaryl, aldicarb, methomyl) are potent acetylcholinesterase inhibitors.

Pathophysiologic Mechanism & Chemical "Aging"

Acetylcholinesterase (AChE) terminates the neurotransmission of acetylcholine (ACh) at parasympathetic postganglionic muscarinic synapses, autonomic ganglia, skeletal muscle neuromuscular junctions (nicotinic), and the central nervous system. Organophosphates bind to the serine hydroxyl active site of AChE, phosphorylating and inactivating the enzyme. This leads to massive, uncontrolled accumulation of acetylcholine across all cholinergic synapses.

Irreversible Inhibition & Chemical "Aging" : The organophosphate-enzyme bond undergoes spontaneous dealkylation (loss of an alkoxy group) over time. Once this dealkylation occurs, the bond is covalent and irreversible—a process termed chemical aging . Aged AChE cannot be reactivated by oximes; new enzyme must be synthesized by the body over weeks. Soman ages within minutes (~2 minutes), whereas sarin ages over 5 hours and VX over 48 hours.

Carbamates vs. Organophosphates : Carbamates carbamylate rather than phosphorylate AChE. This bond is spontaneously reversible through hydrolysis within 24 to 48 hours and does NOT undergo chemical aging . Pralidoxime is generally unnecessary in pure carbamate poisoning unless clinical distinction from organophosphates is impossible.

Clinical Presentation: The Cholinergic Toxidrome

Cholinergic crisis is characterized by simultaneous muscarinic, nicotinic, and central nervous system hyperactivity:

Muscarinic Excess (SLUDGEM / DUMBELS) :

  • D : Defecation / Diarrhea
  • U : Urination
  • M : Miosis (pinpoint pupils)
  • B : Bronchorrhea, Bronchospasm, Bradycardia (The "Killer Bs")
  • E : Emesis
  • L : Lacrimation
  • S : Salivation

Nicotinic Excess (MTWTF) :

  • M : Muscle fasciculations
  • T : Tachycardia (can precede bradycardia due to sympathetic ganglionic stimulation)
  • W : Weakness
  • T : Tremor
  • F : Flaccid diaphragmatic paralysis and respiratory arrest

Central Nervous System : Restlessness, emotional lability, confusion, status epilepticus, and central respiratory center depression.

Important

The "Killer Bs"—Bronchorrhea, Bronchospasm, and Bradycardia —are the direct cause of death in acute cholinergic poisoning. Patients literally drown in their own copious tracheobronchial secretions.

Antidote Resuscitation: Atropine & Pralidoxime (2-PAM)

Loading diagram...

1. Atropine Sulfate: The Muscarinic Antagonist

Mechanism : Competitive antagonist at muscarinic acetylcholine receptors. It blocks parasympathetic stimulation, reversing bronchorrhea, bronchospasm, and bradycardia. Atropine has ZERO effect on nicotinic receptors and will not reverse muscle fasciculations, peripheral weakness, or diaphragmatic paralysis.

Dosing & Escalation : Initial adult dose is 2 to 5 mg IV (pediatrics 0.05 mg/kg). If no clinical improvement occurs within 3 to 5 minutes, double the dose (e.g., 2 mg → \rightarrow → 4 mg → \rightarrow → 8 mg → \rightarrow → 16 mg). In severe organophosphate poisoning, cumulative doses exceeding 100 to 200 mg within 24 hours may be required.

Primary Resuscitation Endpoint of Atropinization :

Clear breath sounds on auscultation (complete drying of tracheobronchial secretions) .

Resolution of bronchospasm .

Heart rate > 80 bpm >80\text{ bpm} > 80 bpm and systolic BP > 90 mmHg >90\text{ mmHg} > 90 mmHg .

Pitfall : Mydriasis is NOT an endpoint for stopping atropine. Pupillary size responds slowly and may be masked by sympathetic ganglionic tone.

Maintenance Infusion : Once pulmonary secretions are controlled, initiate a continuous IV infusion delivering 10% to 20% of the total cumulative loading dose per hour.

2. Pralidoxime Chloride (2-PAM): The Oxime Reactivator

Mechanism : A nucleophilic oxime that attacks the phosphorylated acetylcholinesterase, forming an oxime-phosphate complex that hydrolyzes away, thereby reactivating the functional AChE enzyme . Because it works at nicotinic neuromuscular junctions , it restores skeletal muscle strength and reverses diaphragmatic paralysis. It must be administered before chemical aging occurs.

Dosing : 1 to 2 g IV bolus infused over 15 to 30 minutes (pediatrics: 20 to 50 mg/kg), followed by a continuous infusion of 500 mg/h (pediatrics: 10 to 20 mg/kg/h). Rapid IV administration can precipitate transient hypertension, laryngeal spasm, and muscle rigidity.

3. Adjunctive Seizure Control

Organophosphate-induced status epilepticus causes profound excitotoxic neuropathology. Treat aggressively with intravenous benzodiazepines (diazepam 5 to 10 mg IV or midazolam 5 to 10 mg IV); avoid phenytoin, which is ineffective for toxin-induced seizures.

Cellular Asphyxiants & Cholinergic Antidote Reference Matrix

Toxic Inhalant / Agent Primary Molecular Target Diagnostic Signature Primary Antidote & Dosage Mechanism of Reversal Critical Precautions & Interferences

Cyanide (HCN) Mitochondrial cytochrome c c c oxidase ( Fe 3 + \text{Fe}^{3+} Fe 3 + ) Severe lactic acidosis ( > 8 – 10 mmol/L >8\text{--}10\text{ mmol/L} > 8 – 10 mmol/L ); high ScvO 2 > 90 % \text{ScvO}_2 >90\% ScvO 2 ​ > 90% Hydroxocobalamin (Cyanokit) : 5 g IV over 15 min (repeat 5 g PRN) Coordinates cobalt with cyanide to form cyanocobalamin Dark red urine/skin; false shutdown on CRRT/dialysis; false lab elevations (bilirubin).

Carbon Monoxide (CO) Hemoglobin iron (affinity 200 – 250 × > O 2 200\text{--}250\times > \text{O}_2 200 – 250 × > O 2 ​ ) Elevated COHb on co-oximetry; normal pulse oximetry; metabolic acidosis 100% Normobaric O 2 \text{O}_2 O 2 ​ or Hyperbaric O 2 \text{O}_2 O 2 ​ (HBO) Competitive displacement of CO; shortens half-life to 20–30 min Standard SpO 2 \text{SpO}_2 SpO 2 ​ is falsely normal; HBO required for COHb > 25 % >25\% > 25% , pregnancy > 15 % >15\% > 15% , or syncope.

Organophosphates Acetylcholinesterase (AChE) phosphorylation Muscarinic (Killer Bs) + Nicotinic (muscle weakness, fasciculations) Atropine (2–5 mg IV q3–5m doubled) + Pralidoxime (2-PAM) (1–2 g IV then 500 mg/h) Atropine blocks muscarinic receptors; 2-PAM reactivates AChE at nicotinic synapses Titrate atropine to dry lung sounds, NOT mydriasis; give 2-PAM before chemical aging.